Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study

Rigshospitalet

Status

Completed

Conditions

Hematological Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT06277479

Rigshospitalet. Hematology

Details and patient eligibility

About

The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark. Further, identify demographic, medical or personal factors associated with better self-reported health and quality of life.

Full description

Objective

Method

An observational, descriptive, cross-sectional study using clinical data and self-reported questionnaires to assess the occurrence of comorbidities and self-reported late effects in survivors treated with allo-HSCT in Denmark between 1970 and 2024.

Study population

All survivors treated for malignant or non-malignant hematological disease with allo-HCST at the age of 18-79 years from 1970-2024 in Denmark are eligible (n=1.436).

Endpoints

Self-reported survivorship specific HRQoL measured by EORTC-QOL- Survivorship 100.
Degree of health literacy measured by the Health Literacy Questionnaire (HLQ).
Occurrence or degree of Chronic Graft Versus Host Disease measured by modified Lee Chronic Graft versus host disease Symptom Scale.

Enrollment

1,262 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All survivors treated for malignant or non-malignant hematological disease with allogeneic hematopoietic stem cell transplantation at the age of 18-79 years from 1970-2024 in Denmark are eligible

Exclusion criteria